Lilly's Lasmiditan NDA Review Could Hinge On US FDA's Migraine Guidance
Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva.
You may also be interested in...
Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential
Lilly noted strong growth for new products, but gains seen in the fourth quarter included older products with limited potential going forward. That puts even more pressure on the R&D pipeline and the company's revised guidance, but executives were optimistic about future growth drivers.
Lilly's New Year Resolution: Make New Launches Into Blockbusters
Lilly laid out its 2019 financial forecast and commercial and R&D goals during an investor event in New York. While there were no big surprises, the company updated investors on important catalysts in diabetes, immunology, oncology and pain.